We reported for the first time a high frequency of ATRX loss and ALT in high-grade and diffuse gliomas developing in NF1 patients [39], and more recent studies have also documented ATRX mutations in aggressive NF1-associated gliomas [8, 37]. The gene discussed is NF1; the disease is central nervous system cancer.